Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities.

Gilead and Merck announce positive phase 3 results for once-weekly oral islatravir/lenacapavir, demonstrating noninferiority in virologically suppressed HIV.

Antiretroviral drugs for HIV infection have enabled most people living with the virus to live long and healthy lives.

Antiretroviral drugs for HIV infection have enabled most people living with the virus to live long and healthy lives. However ...

Antiretroviral therapy (ART) has enabled most people living with HIV to live long and healthy lives. However, a small portion of people experience detectable traces of the virus, known as ...

While HIV-1 and HIV-2 closely relate and can cause similar health concerns, there are some important differences to know — especially when it comes to transmission, testing, and treatment. HIV-1 and ...

What Is Idvynso, and Why Does It Matter? Idvynso (doravirine/islatravir) is a fixed-dose combination of two prescription medicines and is taken as a single, once ...

Among some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of ...